莱博雷生多少钱一盒?在哪里购买?

Leborexan is a dual orexin receptor antagonist for the treatment of insomnia. Its price and purchase channels are the focus of patients' attention. Lebraxant produced by Japan's Eisai Company is widely used around the world. Understanding its price system, legal purchasing channels and drug metabolism characteristics is of great significance to optimizing treatment plans.

How much does a box of Lebo Reson cost?

The market price of the Japanese Eisai version varies significantly depending on the specifications. Currently, the commercially available version includes three specifications: 2.5mg, 5mg and 10mg, with prices ranging from US$77 to US$165. This price system reflects the production costs and market demand characteristics of different dosage specifications, and patients can choose the appropriate specifications according to their own treatment needs and economic conditions.

Specifications and Price

Leborexen in 2.5mg format is priced at approximately US$77 per box and is suitable for patients in the initial treatment stage or who require low-dose maintenance. Each box of 100 tablets in 5mg specification is priced at about US$117, and the cost of a single tablet is reduced to US$1.17, which is suitable for long-term medication users. The 10mg high-dose version costs about US$165 per box and is mainly used for intensive treatment of patients with refractory insomnia.

Factors affecting price

In terms of production costs, the content of active ingredients directly affects the cost of raw materials. The input of raw materials for the 10mg specification is twice that of the 5mg version. Differences in packaging specifications lead to 5mg/100 tablets reducing marginal costs through scale effects. Regional price fluctuations are significantly affected by exchange rate changes and import tariffs.

Where to buy Lebraxant?

The legal purchase channels for Lebraxant vary depending on regional medical regulations. It can be obtained through prescription from medical institutions in Japan, while international patients need to obtain it through specific channels. Choosing formal purchasing channels plays a decisive role in ensuring drug quality and therapeutic effects.

Purchasing channels in Japan

Patients can go to Japan, obtain prescriptions from the local hospital’s psychiatric or sleep specialty clinics, and purchase them directly at the hospital pharmacy. They can also go to large chain pharmacies to purchase with a doctor’s prescription. Some regional hospitals provide mailing services, which can cover the medication needs in remote areas.

International patient acquisition methods

Cross-border procurement through international pharmacies authorized by Eisai is the main legal way, and original prescriptions and identity documents are required. Specific pharmacies in some countries have obtained distribution authorization, and patients can purchase it by converting a prescription from a local doctor.

Pharmacokinetics of leborexan

The pharmacokinetic characteristics of leborexan directly affect its clinical efficacy and medication regimen. The drug is rapidly absorbed after oral administration, is mainly metabolized by the liver, and has linear kinetic characteristics. Understanding its metabolic processes can help optimize administration timing and dose adjustment.

Absorption and distribution characteristics

The peak plasma concentration (C_max) is reached 1-3 hours after oral administration, and the bioavailability is approximately 35%. A high-fat diet can delay the peak time to 4 hours, but does not affect the overall degree of absorption. The drug is widely distributed in the body, with an apparent distribution volume of 150L, ​​a protein binding rate of about 90%, and a cerebrospinal fluid concentration that can reach 50% of the plasma level.

Metabolism and elimination pathways

About 70% of drugs are metabolized by the CYP3A4 enzyme system to generate the inactive metabolite M10. The elimination half-life is about 17-19 hours, and steady-state concentration can be reached after 3-5 days of continuous administration.

Patients with renal insufficiency do not need to adjust the dosage, but patients with moderate to severe liver function need to reduce the dosage by 50%. The clearance rate in elderly patients decreases by about 25%, and it is recommended to choose a low-dose starting dose.